

Tisagenlecleucel

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.

The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

Rejected

General description

INN

Tisagenlecleucel

Medicine type

Biological agent

EML status history

Application rejected in 2023 ([TRS 1049](#)) for [Diffuse large B-cell lymphomas](#)

Therapeutic equivalent for

[axicabtagene ciloleucel](#) for [Diffuse large B-cell lymphomas](#).

Wikipedia

[Tisagenlecleucel](#)

DrugBank

[Tisagenlecleucel](#)